ADANI-GREEN-ENERGY
11.3.2024 16:56:29 CET | Business Wire | Press release
Adani Green Energy Limited (AGEL), India’s largest and one of the world’s leading renewable energy (RE) companies, has operationalized cumulative capacity of 1,000 MW solar energy at the world’s largest RE park at Khavda, Gujarat. With this, AGEL has achieved operational capacity of 9,478 MW and continues its journey to the stated goal of 45,000 MW by 2030.
AGEL delivered 1,000 MW in less than 12 months of commencing work at Khavda. This involved installing approximately 2.4 million solar modules. The accelerated progress underscores AGEL’s commitment to India’s goal of achieving 500 GW non-fossil fuel capacity by 2030.
The world’s largest RE plant of 30 GW spans a staggering 538 sq km of barren land, five times the size of Paris. The project is expected to be completed in the next five years and will create over 15,200 green jobs
Leveraging the proven project execution capabilities of Adani Infra, technological expertise of Adani New Industries Limited (ANIL), operational excellence of AIMSL, and robust supply chain, AGEL is set to replicate its success in building and operating India’s first and the world’s largest wind-solar hybrid cluster at Jaisalmer.
AGEL has committed to deploy waterless cleaning robots for the entire solar capacity to address dust accumulation on panels to increase the energy output and help conserve water in the arid Kutch region. This will enable AGEL’s water neutrality goals aligned to United Nations Sustainable Development Goal 6.
About Adani Green Energy Limited
Adani Green Energy Limited (AGEL) is India’s largest and one of the leading renewable energy companies in the world, enabling the clean energy transition. AGEL develops, owns, and operates utility scale grid-connected solar, wind and hybrid renewable power plants. With a locked-in growth trajectory up to 20.8 Gigawatt (GW), AGEL currently has an operating renewable portfolio of over 9 GW, the largest in India, spread across 12 states.
Adani Portfolio companies enabling the development of the Khavda RE plant
Adani Infra India
AIIL is at the forefront of enabling transformative mega-scale infrastructure development through innovative solutions, data-driven insights, and engineering excellence. The company offers Project Management Consultancy (PMC) services for infrastructure projects across varied sectors. AIIL is committed to build smarter, resilient, and sustainable solutions for infrastructure development.
Adani Ports & Special Economic Zone
Adani Ports and Special Economic Zone Ltd (APSEZ), a part of the globally diversified Adani Group, has evolved from a port company to an Integrated Transport Utility providing an end-to-end solution from its port gate to customer gate. It is the largest port developer and operator in India with 7 strategically located ports and terminals on the west coast. Our vision is to be the largest ports and logistics platform in the world in the next decade. With a vision to turn carbon neutral by 2025, APSEZ was the first Indian port and third in the world to sign up for the Science-Based Targets Initiative (SBTi) committing to emission reduction targets to control global warming at 1.5°C above pre-industrial levels.
Adani Energy Solutions
AESL, part of the Adani portfolio, is a multidimensional organization with presence in various facets of the energy domain, namely power transmission, distribution, smart metering, and cooling solutions. AESL is a catalyst for transforming the energy landscape in the most reliable, affordable, and sustainable way.
Ambuja Cements
Ambuja Cements Limited is one of India's leading cement companies and a member of the diversified Adani Group – the largest and fastest growing portfolio of diversified sustainable businesses. Ambuja has been recognized as India’s Most Trusted Cement Brand by TRA Research in its Brand Trust Report, 2023. Ambuja has provided hassle-free, home-building solutions with its unique sustainable development projects and environment-friendly practices since it started operations. To further add value to customers, the company has launched innovative products like Ambuja Plus, Ambuja Cool Walls, Ambuja Compocem and Ambuja Kawach under the umbrella of Ambuja Certified Technology. These products not only fulfil important customer needs but also help in significantly reducing their carbon footprints.
Anil New Industries
Adani New Industries Ltd. (ANIL), a wholly owned subsidiary of Adani Enterprises Limited (AEL), is at the forefront of enabling the energy transition initiatives of the group, across sustainable fuels and green molecules. It is dedicated to bolstering India’s energy security and decarbonization goals globally. The company is adapting and nurturing future technologies in pursuit of providing affordable and sustainable energy for all.
Adani Infrastructure Management Services
Adani Infrastructure Management Services Ltd. (AIMSL) is an end-to-end solutions provider of Operations & Maintenance (O&M) for the energy sector across renewable power plants (Solar & Wind), transmission system & thermal Power Plants. The company operates and maintains one of the largest fleets in the Indian power sector. As a strategic business partner, AIMSL combines the expertise of best-in-class O&M talent, state-of-the-art technologies, and digitalization to deliver operational excellence and reduced O&M costs.
Jash Energy
Jash Energy is a leading manufacturer of solar trackers, a device installed in a solar panel which moves in direction of the sun to capture maximum solar energy for electricity generation. Strategically located at Mundra, the largest private port in India, Jash Energy has easy access to Western, Middle East, and African markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311834182/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom